Extending the clinical benefit of proven cancer therapies

Vicus is employing immunotherapy to selectively target signaling pathways that lead to tumor-promoting inflammation and tumor evasion of the immune system. Our goal is to safely and significantly extend the clinical benefit of proven targeted cancer therapies.

About Vicus
We are an immuno-oncology company developing breakthrough immunotherapies for patients with solid-tumor cancers. We are focused on the development and commercialization of our lead product candidate, VT-122, a immunotherapy for advanced liver cancer patients receiving sorafenib and for pre-chemo prostate cancer patients receiving androgen inhibition therapies.

Recent News

September 8, 2014: Vicus Therapeutics Announces Phase II Data Demonstrating Overall Survival Benefit with VT-122 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Vicus Therapeutics
55 Madison Avenue Suite 400
Morristown NJ 07960
(973) 285-3175

Copyright © 2014 Vicus Therapeutics All Rights Reserved.